Renaud Savary is Senior Investment Analyst, Pharmaceutical Sector, at Avem Capital.

Layoffs are looming in Switzerland as Novartis announces its plans to cut upwards of 550 full-time positions by the end of ...

Psychedelics have demonstrated significant progress, with promising data and increased interest from large companies, ...

Businesses want to be available to provide for employees and be competitive. They want workers to be able to go to the HR ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and ...

AI and computational modeling are reducing reliance on animal testing by simulating human biology, improving drug safety and ...

In today’s Pharmaceutical Executive Daily, Novo Nordisk faces market pressure after a late-stage trial setback, Moderna takes ...

In today’s Pharmaceutical Executive Daily, Novartis plans to eliminate 550 positions at a major Swiss site, the FDA authorizes the first gene therapy for adolescents and adults with spinal muscular ...

Ryan Conrad, visiting fellow at the Center on Health Policy at the Brookings Institution, continues his conversation about ...

Psychedelics have demonstrated significant progress, generating enthusiasm across the neuroscience industry and leading to ...

Cancerguard, a multi-cancer early detection blood test.

Tesaro confirmed its litigation against AnaptysBio in the Delaware Chancery Court in a press release on its website, ...